




Name	Hiroto Inaba, MD, PhD	
Current Position	Member Director, Hematology/Oncology Fellowship Program Interim Director, Leukemia/Lymphoma Division Department of Oncology St. Jude Children's Research Hospital	
Country	United States of America	
Major Field	Acute lymphoblastic leukemia, acute myeloid leukemia	

Educational Background

Mie University School of Medicine, Mie, Japan	MD	03/1991	Medicine
United States Naval Hospital, Yokosuka, Japan	Internship	03/1992	General Medicine
Mie University Hospital, Mie, Japan	Residency	04/1992	Pediatrics
Mie University School of Medicine, Mie, Japan	PhD	03/2000	Immunology
Children's Hospital of Michigan, Detroit, MI	Residency	06/2003	Pediatrics
St. Jude Children's Research Hospital	Fellowship	06/2007	Pediatric Hematology/Oncology

Professional Experience

07/1995-03/1996	Medical Staff, Department of Pediatrics, Mie University Hospital, Mie, Japan
04/2000-06/2000	Assistant Professor, Department of Pediatrics, Mie University School of Medicine, Mie, Japan
07/2007-04/2011	Assistant Member, Leukemia/Lymphoma Division, Department of Oncology, St. Jude Children's Research Hospital Memphis, TN, USA
07/2007-01/2012	Assistant Professor, Department of Pediatrics, University of Tennessee College of Medicine, Memphis, TN, USA
04/2011-09/2018	Associate Member, Leukemia/Lymphoma Division, Department of Oncology, St. Jude Children's Research Hospital Memphis, TN, USA
01/2012-06/2020	Associate Professor, Department of Pediatrics, University of Tennessee College of Medicine, Memphis, TN, USA
09/2018-present	Member, Leukemia/Lymphoma Division, Department of Oncology, St. Jude Children's Research Hospital Memphis, TN, USA
07/2020-present	Professor, Department of Pediatrics, University of Tennessee College of Medicine, Memphis, TN, USA
04/2022-present	Director, Pediatric Hematology/Oncology Fellowship Program, St. Jude Children's Research Hospital, Memphis, TN, USA
05/2022-present	Interim Director, Leukemia/Lymphoma Division, St. Jude Children's Research Hospital, Memphis, TN, USA

Other Experience and Professional Memberships

Member, Japan Pediatric Society
Member, Japanese Society of Hematology
Member, Japanese Society of Pediatric Hematology
Member, American Society of Hematology
Member, Children's Oncology Group
Member, International Society of Paediatric Oncology
Chair of panel, National Comprehensive Cancer Network Practice Guideline for Pediatric Acute Lymphoblastic Leukemia
Scientific Programme Advisory Committee, The International Society of Paediatric Oncology



Main Scientific Publications

1. **Inaba H**, Pui CH. Glucocorticoid use in acute lymphoblastic leukemia. *Lancet Oncol.* 2010;11(11):1096-1106. PubMed Central PMCID: PMC3309707.
2. **Inaba H**, Rubnitz JE, Coustan-Smith E, Li L, Furmanski BD, Mascara GP, Heym KM, Christensen R, Onciu M, Shurtleff SA, Pounds SB, Pui CH, Ribeiro RC, Campana D, Baker SD. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. *J Clin Oncol.* 2011;29(24):3293-3300. PubMed Central PMCID: PMC3158600.
3. **Inaba H**, Coustan-Smith E, Cao X, Pounds SB, Shurtleff SA, Wang KY, Raimondi SC, Onciu M, Jacobsen J, Ribeiro RC, Dahl GV, Bowman WP, Taub JW, Degar B, Leung W, Downing JR, Pui CH, Rubnitz JE, Campana D. Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. *J Clin Oncol.* 2012;30(29):3625-3632. PubMed Central PMCID: PMC3462046.
4. **Inaba H**, Yang J, Kaste SC, Hartford CM, Motosue M, Chemaitilly W, Triplett BM, Shook DR, Pui CH, Leung W. Longitudinal changes in body mass and composition in survivors of childhood hematologic malignancies after allogeneic hematopoietic stem-cell transplantation. *J Clin Oncol.* 2012;30(32):3991-3997. PubMed Central PMCID: PMC3675688.
5. **Inaba H**, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. *Lancet.* 2013;381:1943-1955. PubMed Central PMCID: PMC3816716.
6. **Inaba H**, Zhou Y, Abla O, Adachi S, Auvrignon A, Beverloo HB, de Bont E, Chang TT, Creutzig U, Dworzak M, Elitzur S, Fynn A, Forestier E, Hasle H, Liang DC, Lee V, Locatelli F, Masetti R, De Moerloose B, Reinhardt D, Rodriguez L, Van Roy N, Shen S, Taga T, Tomizawa D, Yeoh AE, Zimmermann M, Raimondi SC. Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study. *Blood.* 2015;126(13):1575-1584. PubMed Central PMCID: PMC4582334.
7. Alexander TB, Gu Z, Iacobucci I, Dickerson K, Choi JK, Xu B, Payne-Turner D, Yoshihara H, Loh ML, Horan J, Buldini B, Basso G, Elitzur S, de Haas V, Zwaan CM, Yeoh A, Reinhardt D, Tomizawa D, Kiyokawa N, Lammens T, De Moerloose B, Catchpoole D, Hori H, Moorman A, Moore AS, Hrusak O, Meshinchi S, Orgel E, Devidas M, Borowitz M, Wood B, Heerema NA, Carroll A, Yang YL, Smith MA, Davidsen TM, Hermida LC, Gesuwan P, Marra MA, Ma Y, Mungall AJ, Moore RA, Jones SJM, Valentine M, Janke LJ, Rubnitz JE, Pui CH, Ding L, Liu Y, Zhang J, Nichols KE, Downing JR, Cao X, Shi L, Pounds S, Newman S, Pei D, Guidry Auvil JM, Gerhard DS, Hunger SP, **Inaba H***, Mullighan CG* (*co-corresponding author). The genetic basis and cell of origin of mixed phenotype acute leukaemia. *Nature.* 2018;562(7727):373-379. PubMed Central PMCID: PMC6195459.
8. **Inaba H**, Panetta JC, Pounds S, Wang L, Li L, Navid F, Federico SM, Eisenmann ED, Vasilyeva A, Wang YD, Shurtleff S, Pui CH, Gruber TA, Ribeiro RC, Rubnitz J, Baker SD. Sorafenib population pharmacokinetics and skin toxicities in children and adolescents with refractory/relapsed leukemia or solid tumor malignancies. *Clin Cancer Res.* 2019;25(24):7320-7330. PubMed Central PMCID: PMC6911639.
9. **Inaba H**, Mullighan CG. Pediatric acute lymphoblastic leukemia. *Haematologica.* 2020;105(11):2524-2539. PubMed Central PMCID: PMC7604619.
10. **Inaba H**, van Oosterwijk JG, Panetta JC, Li L, Buelow DR, Blachly JS, Shurtleff S, Pui CH, Ribeiro RC, Rubnitz JE, Pounds S, Baker SD. Preclinical and pilot study of type I FLT3 tyrosine kinase inhibitor, crenolanib, with sorafenib in acute myeloid leukemia and FLT3-internal tandem duplication. *Clin Cancer Res.* 2022;28(12):2536-2546. PubMed Central PMCID: PMC9197875